C18 Ceramide-d7 (d18:1-d7/18:0) (Synonyms: C18 Ceramide-d7, Cer-d7 (d18:1-d7/18:0), Ceramide-d7 (d18:1-d7/18:0), N-Stearoyl-DSphingosine-d7) |
رقم الكتالوجGC46988 |
An internal standard for the quantification of C18 ceramide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1840942-14-4
Sample solution is provided at 25 µL, 10mM.
C18 Ceramide-d7 is intended for use as an internal standard for the quantification of C18 ceramide by GC- or LC-MS. C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.1 Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.2 It is selectively down-regulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.3
1.Mizutani, Y., Kihara, A., and Igarashi, Y.Mammalian Lass6 and its related family members regulate synthesis of specific ceramidesBiochem J.390(Pt. 1)263-271(2005) 2.Koybasi, S., Senkal, C.E., Sundararaj, K., et al.Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomasJ. Biol. Chem.279(43)44311-44319(2004) 3.Bergman, B.C., Brozinick, J.T., Strauss, A., et al.Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humansDiabetologia59(3)785-791(2016)
Average Rating: 5
(Based on Reviews and 20 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *